Market Overview

Goldman Sachs Suggests Buying Calls on Vertex Pharmaceuticals (VRTX)


Goldman Sachs is out with a research report this morning, where its analysts suggest that traders buy calls on Vertex Pharmaceuticals (NASDAQ: VRTX) ahead of several catalysts.

The analysts expect shares to be especially volatile around seven upcoming catalysts, most relating to TVR (Telaprevir), a new drug for HCV (hepatitis C infection) which could represent over 80% of VRTX sales by next year.

TVR is at the leading edge of a paradigm shift for the treatment of HCV, a market that is expected to grow to $10-$12bn from $3bn following the introduction of new oral drugs, with improved cure rates and shorter treatment durations.

They suggest buying the July $41.00 call for $3.50.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Posted-In: Goldman SachsAnalyst Color Options Trading Ideas


Related Articles (VRTX)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

GLD Meets the Fractal Lazy Man

No retreat for Wheat prices!